A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is expanding ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...

Vertex Pharmaceuticals Incorporated remains a leader in cystic fibrosis treatments, fueling robust cash flow and funding a promising pipeline expansion. VRTX is seeing early but accelerating revenue ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a bullish ...